Bank of New York Mellon’s Y-mAbs Therapeutics YMAB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-99,352
| Closed | -$448K | – | 4280 |
|
|
2025
Q2 | $448K | Buy |
99,352
+6,878
| +7% | +$30.9K | ﹤0.01% | 3564 |
|
|
2025
Q1 | $410K | Buy |
92,474
+25
| +0% | +$145 | ﹤0.01% | 3551 |
|
|
2024
Q4 | $724K | Buy |
92,449
+894
| +1% | +$10.9K | ﹤0.01% | 3336 |
|
|
2024
Q3 | $1.2M | Sell |
91,555
-29,399
| -24% | -$373K | ﹤0.01% | 3029 |
|
|
2024
Q2 | $1.46M | Buy |
120,954
+8,974
| +8% | +$121K | ﹤0.01% | 2972 |
|
|
2024
Q1 | $1.82M | Sell |
111,980
-7,987
| -7% | -$108K | ﹤0.01% | 2810 |
|
|
2023
Q4 | $818K | Buy |
119,967
+362
| +0.3% | +$2.09K | ﹤0.01% | 3296 |
|
|
2023
Q3 | $652K | Buy |
119,605
+1,319
| +1% | +$7.68K | ﹤0.01% | 3411 |
|
|
2023
Q2 | $803K | Buy |
118,286
+5,755
| +5% | +$43.1K | ﹤0.01% | 3332 |
|
|
2023
Q1 | $564K | Sell |
112,531
-809
| -0.7% | -$3.3K | ﹤0.01% | 3434 |
|
|
2022
Q4 | $553K | Sell |
113,340
-15
| -0% | -$109 | ﹤0.01% | 3490 |
|
|
2022
Q3 | $1.63M | Buy |
113,355
+10,698
| +10% | +$177K | ﹤0.01% | 2960 |
|
|
2022
Q2 | $1.55M | Sell |
102,657
-1,478
| -1% | -$17.2K | ﹤0.01% | 2973 |
|
|
2022
Q1 | $1.24M | Buy |
104,135
+790
| +0.8% | +$8.11K | ﹤0.01% | 3181 |
|
|
2021
Q4 | $1.68M | Sell |
103,345
-289
| -0.3% | -$6.18K | ﹤0.01% | 3096 |
|
|
2021
Q3 | $2.96M | Buy |
103,634
+12,008
| +13% | +$378K | ﹤0.01% | 2774 |
|
|
2021
Q2 | $3.1M | Sell |
91,626
-9,284
| -9% | -$298K | ﹤0.01% | 2737 |
|
|
2021
Q1 | $3.05M | Sell |
100,910
-6,849
| -6% | -$281K | ﹤0.01% | 2672 |
|
|
2020
Q4 | $5.33M | Buy |
107,759
+2,650
| +3% | +$123K | ﹤0.01% | 2326 |
|
|
2020
Q3 | $4.04M | Buy |
105,109
+506
| +0.5% | +$20.1K | ﹤0.01% | 2327 |
|
|
2020
Q2 | $4.52M | Buy |
104,603
+19,140
| +22% | +$724K | ﹤0.01% | 2252 |
|
|
2020
Q1 | $2.23M | Buy |
85,463
+1,631
| +2% | +$47.4K | ﹤0.01% | 2494 |
|
|
2019
Q4 | $2.62M | Buy |
83,832
+24,831
| +42% | +$735K | ﹤0.01% | 2654 |
|
|
2019
Q3 | $1.54M | Buy |
59,001
+1,172
| +2% | +$29.9K | ﹤0.01% | 2902 |
|
|
2019
Q2 | $1.32M | Buy |
57,829
+37,609
| +186% | +$864K | ﹤0.01% | 3044 |
|
|
2019
Q1 | $530K | Buy |
+20,220
| New | +$444K | ﹤0.01% | 3521 |
|
Other funds holding YMAB
Bank of New York Mellon's YMAB Position: Q3 2025 in Review
Bank of New York Mellon sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 99,352 shares — an estimated $448K sold.
Bank of New York Mellon first reported a position in YMAB in Q1 2019 and held it in 26 quarters. The position peaked at $5.33M in Q4 2020. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.
- Bank of New York Mellon reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
- Bank of New York Mellon sold 99,352 Y-mAbs Therapeutics shares in Q3 2025, an estimated $448K.
- Bank of New York Mellon first reported a position in Y-mAbs Therapeutics in Q1 2019 and held it in 26 quarters.
- Bank of New York Mellon's Y-mAbs Therapeutics position peaked at $5.33M in Q4 2020.
- 2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.
Based on Bank of New York Mellon's 13F filing for Q3 2025, filed 3 Nov 2025.